Oxford American handbook of oncology. Second Edition. Oxford University Press (2015)
Histone deacetylase (HDAC) is a cellular enzyme that modifies histone proteins and regulates DNA transcription, and may lead to a survival advantage in cancer cells. HDAC inhibitors block this enzyme’s activity and thus slow cancer cell growth.
- Mechanism: inhibits histone deacetylase
- Route: oral
- Uses: cutaneous T-cell lymphoma
- Notes: can cause fatigue, nausea, and myelosuppression. It can lead to elevated PT-INR in patients on warfarin.